Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Nab-Paclitaxel With Iparomlimab and Tuvorilimab in Advanced Gallbladder Cancer
NCT07310069Phase 2Enrolling by invitation
- Sponsor
- Xinhua Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, QL1706 in gallbladder cancer, sponsored by Xinhua Hospital. Started May 2025; status: enrolling by invitation.
02
Drugs
iparomlimabQL1706
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on NCT07310069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310069.